Nuclear Medicine - Zimmermann, Richard
29,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
15 °P sammeln
  • Broschiertes Buch

Nuclear medicine is a specialized medical field based on the application of radiopharmaceuticals, i.e. drugs associated to radioactivity, for diagnosis or therapeutic purposes. In the past fifty years, nuclear medicine has progressed in such a way that it is now a major tool in hospitals. Nowadays, this technology enables to better detect, observe and describe diseases, and also to improve treatments. Cancer therapy is the main application of this speciality. Once injected to the patient, the radiopharmaceutical drug aims selectively at the tumoral cells, including the metastases, settles…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Nuclear medicine is a specialized medical field based on the application of radiopharmaceuticals, i.e. drugs associated to radioactivity, for diagnosis or therapeutic purposes. In the past fifty years, nuclear medicine has progressed in such a way that it is now a major tool in hospitals. Nowadays, this technology enables to better detect, observe and describe diseases, and also to improve treatments. Cancer therapy is the main application of this speciality. Once injected to the patient, the radiopharmaceutical drug aims selectively at the tumoral cells, including the metastases, settles there and emits radiation. Depending on the type of radiation, the drug will either help to identify the cells or to destroy them. Recent breakthroughs in this technology bring new perspectives to oncology, haematology and neurology. At the same time, since the beginning of the 21st century nuclear medicine has also benefited from a double revolution in terms of imaging technology. On the one hand, the Positron Emission Tomography (PET) made a real impact with a polyvalent imaging drug called FDG. On the other hand, a new tool combining functional and morphological imaging (PET-CT) was very recently made available to the medical community. This scientific book aims to introduce nuclear medicine to a larger audience, pointing out, among other things, the difficulties both physicians and patients meet when trying to access new technologies. There are still some issues to overcome, but recent scientific breakthroughs bring great hopes for patients in the near future.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Zimmermann Richard :

Richard Zimmermann est chimiste, Docteur en sciences physique. Il s'est spécialisé en pharmacologie moléculaire. Après une carrière de recherche, il est désormais le Directeur des projets TEP Europe (Tomographie à émission de positons) au sein de CISBio-Shering. (au moment de la parution de l'ouvrage)

-------------



RICHARD ZIMMERMANN has spent fifteen years in the research departments of conventional pharmaceutical industries based in France, Germany, and the Netherlands, in fields such as cardiology, immunology, and gastroenterology. Since 1999, he has been actively involved in the industrial nuclear medicine field. He started as Head of Research and Development at Saclay, France; he then became Head of PET Business Europe, and was later appointed Head of Business
Development for a large radiopharmaceutical group. He has been an independent consultant since 2012 (Chrysalium Consulting); in addition, he is the chairman of two companies which are active in this field, and he is a board member and advisory board member of several other radiopharmaceutical companies. He has also initiated - and currently chairs - the Oncidium Foundation, aiming to promote radiotherapeutics.